Associated Papers
Interaction of CYP2C19 with the effect of clopidogrel in secondary prevention of major ischemic events: Systematic review and meta-analysis.
Kremers FC et al.
International Journal of Stroke : Official Journal of the International Stroke Society, 2026
Association of CYP2C19 Single Nucleotide Polymorphism With Hemorrhagic Cystitis After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation.
Zhang W et al.
Clinical Transplantation, 2026
Pharmacogenetic influence on bupropion bioactivation and clinical outcomes in major depressive disorder.
Kharasch ED et al.
The Journal of Pharmacology and Experimental Therapeutics, 2026
Assessing the influence of CYP2C9 and CYP2C19 genotypes on the metabolism of CBD-cannabis after controlled single and repetitive consumption.
Schulte J et al.
International Journal of Legal Medicine, 2026
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
Case Report: Severe SIADH and QTc prolongation induced by escitalopram-quetiapine interaction in a CYP2C19 intermediate metabolizer at therapeutic doses.
Jiang Z et al.
Frontiers in Pharmacology, 2026
Donor and recipient genetic polymorphisms modulate tacrolimus pharmacokinetics during voriconazole co-therapy: a drug-drug interaction study in liver transplant recipients.
Li J et al.
Therapeutic Advances in Drug Safety, 2026
Association Between CYP2C9 and CYP2C19 Genetic Polymorphisms and Antiseizure Medication-Induced Adverse Reactions Among Peruvian Patients with Epilepsy.
Alvarado AT et al.
Pharmaceuticals (basel, Switzerland), 2025
Genetics of childhood tuberculosis: A scoping review.
Pinheiro Mascarenhas MA et al.
Paediatric Respiratory Reviews, 2025
Single-tube Lambda exonuclease-mediated LbuCas13a detect of ssDNA for single-nucleotide polymorphisms genotyping.
Luo S et al.
Biosensors & Bioelectronics, 2025
CYP2C19 Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke.
Chen Y et al.
Stroke, 2025
An Investigational Study on the Role of ADME Agents' Genetic Variation on DD217 Pharmacokinetics and Safety Profile.
Sychev DA et al.
Pharmaceuticals (basel, Switzerland), 2025
The role of genetic polymorphisms on drug response in Alzheimer's disease: a systematic review.
Climacosa FMM et al.
Bmc Medical Genomics, 2025
Association of Omeprazole-Related Myopathy With Drug-Drug and Drug-Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case-Control Study.
Jeong E et al.
Pharmacotherapy, 2025
Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India.
Bharath G et al.
Scientific Reports, 2025
XBP1 expression in pancreatic islet cells is associated with poor glycaemic control especially in young non-obese onset diabetes across ancestries.
Siddiqui MK et al.
Communications Medicine, 2025
CYP2C19 Loss-of-Function Is an Independent Risk Factor of Coronary Artery Disease in Patients With Hypertension.
Wei G et al.
Journal of Clinical Laboratory Analysis, 2025
Influence of pharmacokinetics-related gene polymorphisms on plasma levels of clozapine and its metabolites in Japanese patients with schizophrenia.
Kinoshita S et al.
Pcn Reports : Psychiatry and Clinical Neurosciences, 2025
Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.
Naderi N et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025
Hepatic Cytochrome P450 Enzymatic System Interaction With Platelet Function and Cardiovascular Outcomes-Pharmacogenomic Impact on Inter-Organ Communication.
Figueiral M et al.
Comprehensive Physiology, 2025
CYP2C19-Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients.
Katada Y et al.
Clinical and Translational Science, 2025
Pharmacogenetic Implications for Antidepressant Therapy in Major Depression: A Systematic Review Covering 2019-2024.
Fornaguera A et al.
Journal of Clinical Medicine, 2025
Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population.
Hikino K et al.
British Journal of Clinical Pharmacology, 2025
Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine.
Díaz-Villamarín X et al.
Journal of Personalized Medicine, 2025
The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease.
Haj Saleh N et al.
Bmc Cardiovascular Disorders, 2025
The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing.
Akkaif MA et al.
Cardiovascular Drugs and Therapy, 2025
Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19.
Park HJ et al.
Archives of Pharmacal Research, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
Cytochrome P450 17 (CYP17), CYP2C19*2, CYP2C19*3 Gene Polymorphisms and Gastrointestinal Cancer Risk in Rural Maharashtra: A Hospital based Case-Control Study.
Datkhile KD et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2025
French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten.
Lebreton L et al.
Clinical Pharmacology and Therapeutics, 2025
Additive interaction between CYP2C19AA gene polymorphism and Lp(a) on the prognosis of stroke patients.
Peng D et al.
American Journal of Translational Research, 2025
Prevalence of CYP2C19 Variants in Patients with Cardiovascular Disease from the Yunnan-Guizhou Plateau in Southwestern China.
Li XP et al.
Pharmacogenomics and Personalized Medicine, 2025
Impact of cyclosporine A-related single nucleotide polymorphisms on post-transplant outcomes in pediatric hematologic malignancy patients undergoing allogeneic hematopoietic stem cell transplantation.
Ji Q et al.
Frontiers in Immunology, 2025
In vitro assessment of the impact of 30 CYP2C19 variants on citalopram metabolism.
Wang P et al.
Peerj, 2025
Post-transplant complications revealed by mycophenolate mofetil related transporters and metabolic enzymes gene polymorphisms in pediatric patients with hematological disorders.
Ji Q et al.
Bmc Cancer, 2024
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
Roncato R et al.
Jama Network Open, 2024
Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity.
Shoji K et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, 2024
Lipid storage myopathy associated with sertraline treatment is an acquired mitochondrial disorder with respiratory chain deficiency.
Hedberg-Oldfors C et al.
Acta Neuropathologica, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI/non-TCA antidepressants.
Beunk L et al.
European Journal of Human Genetics : Ejhg, 2024
CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania.
Mugusi S et al.
British Journal of Clinical Pharmacology, 2024
CYP2C19 Genetic Variants and Major Depressive Disorder: A Systematic Review.
Bonasser LSS et al.
Pharmaceuticals (basel, Switzerland), 2024
CYP2C19 loss-of-function variants are independent risk factors for premature cerebral infarction: a hospital based retrospective study.
Shi Y et al.
Bmc Cardiovascular Disorders, 2024
CYP3A4*1B but Not CYP3A5*3 as Determinant of Long-Term Tacrolimus Dose Requirements in Spanish Solid Organ Transplant Patients.
Concha J et al.
International Journal of Molecular Sciences, 2024
Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.
Cavallari LH et al.
Interventional Cardiology Clinics, 2024
CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association.
Pereira NL et al.
Circulation, 2024